MX2016007066A - Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. - Google Patents
Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.Info
- Publication number
- MX2016007066A MX2016007066A MX2016007066A MX2016007066A MX2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A
- Authority
- MX
- Mexico
- Prior art keywords
- wnt pathway
- identification
- pathway inhibitors
- biomarkers associated
- predictive biomarkers
- Prior art date
Links
- 229940121396 wnt pathway inhibitor Drugs 0.000 title abstract 4
- 239000000092 prognostic biomarker Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910663P | 2013-12-02 | 2013-12-02 | |
| US201461975339P | 2014-04-04 | 2014-04-04 | |
| PCT/US2014/068097 WO2015084808A1 (en) | 2013-12-02 | 2014-12-02 | Identification of predictive biomarkers associated with wnt pathway inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007066A true MX2016007066A (es) | 2016-09-08 |
Family
ID=53274023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007066A MX2016007066A (es) | 2013-12-02 | 2014-12-02 | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3077546A4 (enExample) |
| JP (1) | JP2017501137A (enExample) |
| CN (1) | CN105829547A (enExample) |
| AU (1) | AU2014357354A1 (enExample) |
| CA (1) | CA2931975A1 (enExample) |
| HK (1) | HK1223657A1 (enExample) |
| MX (1) | MX2016007066A (enExample) |
| TW (1) | TW201610168A (enExample) |
| WO (1) | WO2015084808A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US20180223372A1 (en) * | 2015-08-03 | 2018-08-09 | Oncomed Pharmaceutical, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| JP2018532720A (ja) * | 2015-09-16 | 2018-11-08 | トビラ セラピューティクス， インコーポレイテッド | 線維症の治療のためのセニクリビロック併用療法 |
| CA3041325A1 (en) * | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CN106990245B (zh) * | 2017-04-05 | 2018-07-31 | 东南大学 | 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN110835372B (zh) * | 2019-11-06 | 2020-12-01 | 上海健康医学院 | 一种靶向Frizzled7单克隆抗体及其制备方法与应用 |
| JP7593584B2 (ja) * | 2020-03-10 | 2024-12-03 | 学校法人杏林学園 | 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN115337400A (zh) * | 2021-05-13 | 2022-11-15 | 中国科学院分子细胞科学卓越创新中心 | 诊断和治疗肿瘤的试剂及其用途 |
| CN113293212A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用 |
| JPWO2023113013A1 (enExample) * | 2021-12-17 | 2023-06-22 | ||
| EP4680969A1 (en) * | 2023-03-15 | 2026-01-21 | Deutsches Krebsforschungszentrum | Cancer stratification and treatment |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| EP1194549A2 (en) * | 1999-07-02 | 2002-04-10 | Chiron Corporation | Human genes and gene expression products |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004032838A2 (en) * | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Methods for treating cancer by inhibiting wnt signaling |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| CA2628255C (en) | 2005-10-31 | 2016-04-19 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| AU2007292242A1 (en) | 2006-09-08 | 2008-03-13 | Genentech, Inc. | Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders |
| DK2066694T3 (en) | 2006-09-29 | 2016-02-08 | Oncomed Pharm Inc | Compositions and Methods for Diagnosing and Treating Cancer |
| WO2008039071A2 (en) * | 2006-09-29 | 2008-04-03 | Agendia B.V. | High-throughput diagnostic testing using arrays |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| EP2238154B1 (en) | 2008-01-18 | 2015-09-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
| SG190568A1 (en) * | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| US20100169025A1 (en) * | 2008-10-10 | 2010-07-01 | Arthur William T | Methods and gene expression signature for wnt/b-catenin signaling pathway |
| US20120053079A1 (en) * | 2009-03-06 | 2012-03-01 | University Of South Alabama | Methods and compositions for the diagnosis, prognosis and treatment of cancer |
| AU2011205409B2 (en) | 2010-01-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Wnt-binding agents and uses thereof |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| EP2788378A4 (en) * | 2011-12-09 | 2015-09-09 | Oncomed Pharm Inc | COMBINATION THERAPY FOR CANCER TREATMENT |
-
2014
- 2014-12-02 CA CA2931975A patent/CA2931975A1/en not_active Abandoned
- 2014-12-02 AU AU2014357354A patent/AU2014357354A1/en not_active Abandoned
- 2014-12-02 WO PCT/US2014/068097 patent/WO2015084808A1/en not_active Ceased
- 2014-12-02 HK HK16111927.7A patent/HK1223657A1/zh unknown
- 2014-12-02 TW TW103141799A patent/TW201610168A/zh unknown
- 2014-12-02 EP EP14867583.8A patent/EP3077546A4/en not_active Withdrawn
- 2014-12-02 MX MX2016007066A patent/MX2016007066A/es unknown
- 2014-12-02 CN CN201480065718.7A patent/CN105829547A/zh active Pending
- 2014-12-02 JP JP2016535646A patent/JP2017501137A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014357354A1 (en) | 2016-06-09 |
| CN105829547A (zh) | 2016-08-03 |
| TW201610168A (zh) | 2016-03-16 |
| WO2015084808A4 (en) | 2015-08-13 |
| HK1223657A1 (zh) | 2017-08-04 |
| JP2017501137A (ja) | 2017-01-12 |
| WO2015084808A1 (en) | 2015-06-11 |
| EP3077546A1 (en) | 2016-10-12 |
| EP3077546A4 (en) | 2017-04-26 |
| CA2931975A1 (en) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016007066A (es) | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. | |
| IL261353A (en) | idh1 suppressors for the treatment of hematological malignancies and solid tumors | |
| LT3198033T (lt) | Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi | |
| PH12017500293A1 (en) | Boronic acid derivatives | |
| MX2017004037A (es) | Derivados de acido boronico. | |
| MX383296B (es) | Vigilancia del tratamiento y pronóstico de los trastornos de la proliferación utilizando inhibidores de la vía de hedgehog. | |
| EP3414692A4 (en) | HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| MX2017004043A (es) | Derivados de acido boronico. | |
| EP3119908A4 (en) | Determining cancer aggressiveness, prognosis and responsiveness to treatment | |
| MX370336B (es) | Derivados de acido boronico. | |
| HK1231513A1 (zh) | 活化素抑制劑應答預測和用於治療的用途 | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| MX2012009030A (es) | Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa. | |
| EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| MX2018006781A (es) | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. | |
| MX2014011500A (es) | Diagnosticos y tratamientos relacionados a inhibidores her3. | |
| EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
| EA201491701A1 (ru) | Лечение рака ингибиторами tor киназы | |
| MX375716B (es) | Método para tratar adenocarcinoma de pulmón. | |
| MX2015011428A (es) | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. | |
| PH12018502570B1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| MX2015006538A (es) | Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa. |